Sanford C. Bernstein
https://www.bernsteinresearch.comSanford C. Bernstein, a division of AllianceBernstein, is a research firm.
View Older Stories View More Recent Stories
-
Bernstein SocGen Group Starts Trip.com Group Limited (TCOM) at Outperform
-
Bernstein SocGen Group Downgrades Reckitt Benckiser (RKT:LN) (RBGLY) to Market Perform
-
Exclusive-Ambani's Reliance Jio IPO set for 2025, retail debut much later, sources say
-
How crowded are software stocks? Bernstein answers
-
Should investors be worried about pricing in the future GLP-1 market?
-
US election scenarios and their implications for renewable stocks
-
Locus Chain and Creta's vision were introduced in New York, hosted by Lloyds Capital and Mike Pompeo
-
WaterTower Music Releases Juror #2 (Original Motion Picture Soundtrack) Music By Mark Mancina
-
Tom Davidson Joins Leerink Partners as Co-President and Co-Head of Global Investment Banking
-
STRIVE LAUNCHES NEW WEALTH MANAGEMENT BUSINESS TO OFFER TRUE FINANCIAL FREEDOM TO AMERICAN CLIENTS
-
Amazon.com (AMZN) PT Raised to $235 at Bernstein SocGen Group
-
Apple reports earnings after the bell. Here's what analysts are expecting
-
Starbucks (SBUX) PT Lowered to $108 at Barclays
-
Bernstein SocGen Group Downgrades Arm Holdings (ARM) to Underperform
-
Societe Generale: Third quarter 2024 earnings
-
Unitil Corp. (UTL) Appoints Jane Lewis-Raymond to its Board
-
Unitil Elects a New Member of the Board of Directors
-
Brinker Int'l (EAT) PT Raised to $95 at Barclays
-
EBay forecasts revenue below estimates on weak demand, shares fall
-
Judicate West Welcomes Polina Bernstein in Los Angeles
-
Bernstein SocGen Group Upgrades Burberry Group PLC (BRBY:LN) (BBRYF) to Outperform
-
Bernstein SocGen Group Reiterates Market Perform Rating on AMD (AMD)
-
Bernstein SocGen Group Downgrades Boeing (BA) to Market Perform
-
Chipotle Mexican Grill (CMG) PT Raised to $60 at Barclays
-
AMD shares slump as forecast disappoints AI-focused investors
-
Bernstein lists 8 large cap Japanese stocks for Growth and Quality investors
-
5 frequently asked questions and answers on Election prediction markets
-
Table22 Closes $11M Series A to Power Food and Beverage Merchants' E-Commerce Growth
-
FTV Capital Named to Inc.’s Founder-Friendly Investors List for Fourth Consecutive Year
-
Apple set for biggest revenue jump in two years on iPhone demand in China
-
Cruise operators reap benefits of their own private islands
-
Lufthansa reports 9% drop in third-quarter profit as core brand struggles
-
Top 10 questions Tesla investors are asking after earnings: Bernstein answers
-
The MoneyShow Alternative Investing Virtual Expo to Take Place Nov. 12-14, 2024
-
Tickets on Sale Now for the 24th Annual Food Network South Beach Wine & Food Festival Presented by Capital One
-
The Hartford Announces New Leadership Appointments In Global Specialty
-
Here's what to expect when Intel and AMD report earnings
-
Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform
-
Acadia Realty Trust Reports Third Quarter Operating Results
-
Microsoft's AI demand under scrutiny as investors seek payday
-
Analysis-Musk's bold 2025 prediction on Tesla sales faces skepticism, scrutiny
-
Bernstein SocGen Group Reiterates Underperform Rating on Tesla (TSLA)
-
Bernstein SocGen Group Reiterates Outperform Rating on Coupang Inc (CPNG)
-
Bernstein SocGen Asks on Global Payments (GPN): 'Ready for a potential activist?'
-
Bernstein SocGen Group Starts StandardAero Inc (SARO) at Outperform
-
Is this stock ready for an activist investor? Bernstein weighs in
-
Indusind Bank Ltd (IIB:IN) PT Lowered to INR1,300 at Bernstein SocGen Group
-
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
-
Maze Therapeutics Reports Positive First-in-Human Data From Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (AKD)
-
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

